{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T06:58:39Z","timestamp":1772953119772,"version":"3.50.1"},"reference-count":197,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Since the global epidemic of the coronavirus disease 2019 (COVID-19), a large number of immunological studies related to COVID-19 have been published in various immunology journals. However, the results from these studies were discrete, and no study summarized the important immunological information about COVID-19 released by these immunology journals. This study aimed to comprehensively summarize the knowledge structure and research hotspots of COVID-19 published in major immunology journals through bibliometrics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Publications on COVID-19 in major immunology journals were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, and R-bibliometrix were comprehensively used for bibliometric and visual analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>1,331 and 5,000 publications of 10 journals with high impact factors and 10 journals with the most papers were included, respectively. The USA, China, England, and Italy made the most significant contributions to these papers. University College London, National Institute of Allergy and Infectious Diseases, Harvard Medical School, University California San Diego, and University of Pennsylvania played a central role in international cooperation in the immunology research field of COVID-19. Yuen Kwok Yung was the most important author in terms of the number of publications and citations, and the H-index. <jats:italic>CLINICAL INFECTIOUS DISEASES<\/jats:italic> and <jats:italic>FRONTIERS IN IMMUNOLOGY<\/jats:italic> were the most essential immunology journals. These immunology journals mostly focused on the following topics: \u201cDelta\/Omicron variants\u201d, \u201ccytokine storm\u201d, \u201cneutralization\/neutralizing antibody\u201d, \u201cT cell\u201d, \u201cBNT162b2\u201d, \u201cmRNA vaccine\u201d, \u201cvaccine effectiveness\/safety\u201d, and \u201clong COVID\u201d.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1035151","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T05:19:29Z","timestamp":1667193569000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiefeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongfa","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.09.011","article-title":"Localized delivery of nanomedicine and antibodies for combating covid-19","author":"Tu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1038\/s41467-022-32867-z","article-title":"Circulating multimeric immune complexes contribute to immunopathology in covid-19","volume":"13","author":"Ankerhold","year":"2022","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00430-022-00743-8","article-title":"Immune complexes as culprits of immunopathology in severe covid-19","author":"Kolb","year":"2022","journal-title":"Med Microbiol Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0155321","DOI":"10.1128\/spectrum.01553-21","article-title":"Multiple routes of antibody-dependent enhancement of sars-Cov-2 infection","volume":"10","author":"Okuya","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100995","article-title":"Complement activation in covid-19 and targeted therapeutic options: A scoping review","volume":"100995","author":"Lim","year":"2022","journal-title":"Blood Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","article-title":"The state of complement in covid-19","volume":"22","author":"Afzali","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jaci.2021.11.004","article-title":"Severe covid-19 is associated with hyperactivation of the alternative complement pathway","volume":"149","author":"Boussier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108450","article-title":"The first case of covid-19 treated with the complement C3 inhibitor Amy-101","volume":"215","author":"Mastaglio","year":"2020","journal-title":"Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2600-6","article-title":"Association of covid-19 inflammation with activation of the C5a-C5ar1 axis","volume":"588","author":"Carvelli","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00425-7","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe coronavirus disease 2019","volume":"10","author":"McEneny-King","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261113","article-title":"Eculizumab in patients with severe coronavirus disease 2019 (Covid-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study","volume":"16","author":"Ruggenenti","year":"2021","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00365-4","article-title":"Complement C5a inhibition: A new form of covid-19 treatment for mechanically ventilated patients","author":"Kalil","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/1389203723666220811121803","article-title":"Sars-Cov-2 infection and C1-esterase inhibitor: Camouflage pattern and new perspective","author":"Al-Kuraishy","year":"2022","journal-title":"Curr Protein Pept Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12931-022-02126-2","article-title":"Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with covid-19: An open-label randomized controlled trial","volume":"23","author":"De Leeuw","year":"2022","journal-title":"Respir Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108598","article-title":"Complement C3 vs C5 inhibition in severe covid-19: Early clinical findings reveal differential biological efficacy","volume":"220","author":"Mastellos","year":"2020","journal-title":"Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.72544","article-title":"Friend or foe? implication of the autophagy-lysosome pathway in sars-Cov-2 infection and covid-19","volume":"18","author":"He","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of sars-Cov-2 on virus entry and its immune cross-reactivity with sars-cov","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-em structure of the 2019-ncov spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2079426","article-title":"Ace2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes sars-Cov-2 and its prevalent variants","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1101\/2021.06.25.449893","article-title":"Circulating immune complexes drive immunopathology in covid-19","volume":"13","author":"Ankerhold","year":"2021","journal-title":"bioRxiv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116063","article-title":"Covid-19 vaccine effectiveness in new York state","volume":"386","author":"Rosenberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of covid-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of sars-Cov-2 vaccines: Pfizer, moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00416-9","article-title":"Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of covid-19 over an 8-month period: A randomised, double-blind, placebo-controlled trial","volume":"22","author":"Herman","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of covid-19 (Tackle): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00215-6","article-title":"Tixagevimab-cilgavimab for treatment of patients hospitalised with covid-19: A randomised, double-blind, phase 3 trial","volume":"10","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s42003-022-03630-3","article-title":"A panel of nanobodies recognizing conserved hidden clefts of all sars-Cov-2 spike variants including omicron","volume":"5","author":"Maeda","year":"2022","journal-title":"Commun Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103960","article-title":"A potent alpaca-derived nanobody that neutralizes sars-Cov-2 variants","volume":"25","author":"Weinstein","year":"2022","journal-title":"iScience"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.11.483867","article-title":"Accelerating perx reaction enables covalent nanobodies for potent neutralization of sars-Cov-2 and variants","volume":"8","author":"Yu","year":"2022","journal-title":"Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2201433119","article-title":"Dromedary Camel Nanobodies Broadly Neutralize Sars-Cov-2 Variants","volume":"119","author":"Hong","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021107985","article-title":"Neutralization of sars-Cov-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies","volume":"40","author":"G\u00fcttler","year":"2021","journal-title":"EMBO J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.933555","article-title":"Global trends in nursing-related research on covid-19: A bibliometric analysis","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1589\/jpts.33.903","article-title":"The hotspots and trends of coronavirus disease 2019 (Covid-19) and physical therapy: A bibliometric and visual analysis","volume":"33","author":"Li","year":"2021","journal-title":"J Phys Ther Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.713487","article-title":"Mapping trends and hotspots regarding clinical research on covid-19: A bibliometric analysis of global research","volume":"9","author":"Xia","year":"2021","journal-title":"Front Public Health"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/jcm10071340","article-title":"Impact of covid-19 at the ocular level: A citation network study","volume":"10","author":"Sanchez-Tena","year":"2021","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.918483","article-title":"Mapping knowledge landscapes and emerging trends of the links between bone metabolism and diabetes mellitus: A bibliometric analysis from 2000 to 2021","volume":"10","author":"Cheng","year":"2022","journal-title":"Front Public Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/asi.22968","article-title":"Patterns of connections and movements in dual-map overlays: A new method of publication portfolio analysis","volume":"65","author":"Chen","year":"2014","journal-title":"J Assoc Inf Sci Technol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.895552","article-title":"Knowledge mapping of multicriteria decision analysis in healthcare: A bibliometric analysis","volume":"10","author":"Dai","year":"2022","journal-title":"Front Public Health"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to sars-Cov-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (Covid-19) in wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerging Microbes Infections"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.04.028","article-title":"A longitudinal study on the mental health of general population during the covid-19 epidemic in China","volume":"87","author":"Wang","year":"2020","journal-title":"Brain Behav And Immun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa149","article-title":"Consistent detection of 2019 novel coronavirus in saliva","volume":"71","author":"To","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1729071","article-title":"Molecular and serological investigation of 2019-ncov infected patients: Implication of multiple shedding routes","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerging Microbes Infections"},{"key":"B46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbi.2020.03.031","article-title":"Nervous system involvement after infection with covid-19 and other coronaviruses","volume":"87","author":"Wu","year":"2020","journal-title":"Brain Behav And Immun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa310","article-title":"Profiling early humoral response to diagnose novel coronavirus disease (Covid-19)","volume":"71","author":"Guo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (Rbd) of 2019 novel coronavirus: Implication for development of rbd protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19-Interim who solidarity trial results","volume":"384","year":"2021","journal-title":"New Engl J Of Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with covid-19 a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"Jama-Journal Of Am Med Assoc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.850260","article-title":"The world health organization's frontline support to countries during the covid-19 pandemic in 2020","volume":"10","author":"Coates","year":"2022","journal-title":"Front Public Health"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.02.038","article-title":"Who guidance on covid-19 vaccine trial designs in the context of authorized covid-19 vaccines and expanding global access: Ethical considerations","volume":"40","author":"Singh","year":"2022","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(21)00266-4","article-title":"Who international standard for evaluation of the antibody response to covid-19 vaccines: Call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.648660","article-title":"Sars-Cov-2 viral shedding and transmission dynamics: Implications of who covid-19 discharge guidelines","volume":"8","author":"Badu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B55","volume-title":"Drugs to prevent covid-19: A who living guideline","year":"2021"},{"key":"B56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1186\/s12913-022-08035-w","article-title":"Coordination mechanisms for covid-19 in the who regional office for Africa","volume":"22","author":"Ngoy","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"LANCET"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"New Engl J Of Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"New Engl J Of Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/vaccines9020160","article-title":"Covid-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates","volume":"9","author":"Sallam","year":"2021","journal-title":"VACCINES"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (Covid-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front In Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.08.043","article-title":"Acceptability of a covid-19 vaccine among adults in the united states: How many people would get vaccinated","volume":"38","author":"Reiter","year":"2020","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.041","article-title":"Intention to participate in a covid-19 vaccine clinical trial and to get vaccinated against covid-19 in France during the pandemic","volume":"38","author":"Detoc","year":"2020","journal-title":"Vaccine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.010","article-title":"Predictors of intention to vaccinate against covid-19: Results of a nationwide survey","volume":"39","author":"Ruiz","year":"2021","journal-title":"Vaccine"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for covid-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.021","article-title":"Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey","volume":"38","author":"Wang","year":"2020","journal-title":"VACCINE"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.12.083","article-title":"Acceptance of the covid-19 vaccine based on the health belief model: A population-based survey in Hong Kong","volume":"39","author":"Wong","year":"2021","journal-title":"VACCINE"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-2961","article-title":"A bibliometric analysis and visualization of photothermal therapy on cancer","volume":"10","author":"Wang","year":"2021","journal-title":"Transl Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.772386","article-title":"Knowledge domain and emerging trends in podocyte injury research from 1994 to 2021: A bibliometric and visualized analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of sars-Cov-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"B72","article-title":"Characteristics and management of sars-Cov-2 delta variant-induced covid-19 infections from may to October 2021 in China: Post-vaccination infection cases","volume":"14","author":"Xiang","year":"2022","journal-title":"Am J Transl Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.abi4506","article-title":"Chimeric spike mrna vaccines protect against sarbecovirus challenge in mice","volume":"373","author":"Martinez","year":"2021","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.01.042","article-title":"Bacteria-enabled oral delivery of a replicon-based mrna vaccine candidate protects against ancestral and delta variant sars-Cov-2","volume":"30","author":"Jawalagatti","year":"2022","journal-title":"Mol Ther"},{"key":"B75","unstructured":"Classification of omicron (B. 1.1. 529): Sars-Cov-2 variant of concern"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27927","article-title":"Omicron (Ba.1) and Sub-variants (Ba.1.1, Ba.2, and Ba.3) of sars-Cov-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment","volume":"94","author":"Kumar","year":"2022","journal-title":"J Med Virol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.898463","article-title":"The omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children","volume":"10","author":"Setiabudi","year":"2022","journal-title":"Front Pediatr"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2381","article-title":"Evolution of the sars-Cov-2 omicron variants Ba.1 to Ba.5: Implications for immune escape and transmission","volume":"32","author":"Shrestha","year":"2022","journal-title":"Rev Med Virol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of sars-Cov-2 omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1038\/s41467-022-32396-9","article-title":"Omicron Ba.4\/Ba.5 escape neutralizing immunity elicited by Ba.1 infection","volume":"13","author":"Khan","year":"2022","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"Ba.2.12.1, Ba.4 and Ba.5 escape antibodies elicited by omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41392-022-01146-0","article-title":"Limited cross-variant neutralization after primary omicron infection: Consideration for a variant-containing booster","volume":"7","author":"Marcotte","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic sars-Cov-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of sars-Cov-2 omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01996-22","article-title":"Neutralization titers in vaccinated patients with sars-Cov-2 delta breakthrough infections","volume":"13","author":"Zou","year":"2022","journal-title":"mBio"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.877101","article-title":"Sars-Cov-2 omicron variant: Epidemiological features, biological characteristics, and clinical significance","volume":"13","author":"Guo","year":"2022","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(21)00217-2","article-title":"Neutralisation of Zf2001-elicited antisera to sars-Cov-2 variants","volume":"2","author":"Zhao","year":"2021","journal-title":"Lancet Microbe"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00836-z","article-title":"Increased immune escape of the new sars-Cov-2 variant of concern omicron","volume":"19","author":"Hu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of Bnt162b2 vaccine against omicron variant in south Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119358","article-title":"Third Bnt162b2 vaccination neutralization of sars-Cov-2 omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2030200","article-title":"Homologous or heterologous booster of inactivated vaccine reduces sars-Cov-2 omicron variant escape from neutralizing antibodies","volume":"11","author":"Wang","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B92","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"Mrna-based covid-19 vaccine boosters induce neutralizing immunity against sars-Cov-2 omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2119912","article-title":"Sars-Cov-2 omicron variant neutralization after mrna-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other sars-Cov-2 variants to immune sera elicited by vaccines after boost","volume":"11","author":"Ai","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of covid-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science"},{"key":"B96","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in covid-19 patients with severe respiratory failure","volume":"27","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B97","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.chom.2020.04.017","article-title":"Heightened innate immune responses in the respiratory tract of covid-19 patients","volume":"27","author":"Zhou","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe covid-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd7114","article-title":"Comprehensive mapping of immune perturbations associated with severe covid-19","volume":"5","author":"Kuri-Cervantes","year":"2020","journal-title":"Sci Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/ni969","article-title":"Similarities and differences in Cd4+ and Cd8+ effector and memory T cell generation","volume":"4","author":"Seder","year":"2003","journal-title":"Nat Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nri3802","article-title":"Memory b cells","volume":"15","author":"Kurosaki","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01355-0","article-title":"Delayed production of neutralizing antibodies correlates with fatal covid-19","volume":"27","author":"Lucas","year":"2021","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional sars-Cov-2-Specific T cells associates with rapid viral clearance and mild disease in covid-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"B104","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to sars-Cov-2 in acute covid-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to sars-Cov-2 and covid-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00460-4","article-title":"Cross-reactive memory T cells and herd immunity to sars-Cov-2","volume":"20","author":"Lipsitch","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00743-3","article-title":"Sars-Cov-2-Specific T cells in infection and vaccination","volume":"18","author":"Bertoletti","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against sars-Cov-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with covid-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild covid-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific Cd4(+) T cells is associated with coordinated humoral and cellular immunity to sars-Cov-2 mrna vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01386-7","article-title":"Cd8(+) T cells contribute to survival in patients with covid-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.953022","article-title":"The differentiation and maintenance of sars-Cov-2-Specific follicular helper T cells","volume":"12","author":"Wang","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101505","article-title":"Buggert m","volume":"55","author":"Niessl","year":"2021","journal-title":"T Cell Immun to Sars-Cov-2. Semin Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00716-1","article-title":"Disentangling the relative importance of T cell responses in covid-19: Leading actors or supporting cast","volume":"22","author":"Kent","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B116","unstructured":""},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the Bnt162b2 mrna covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the Bnt162b2 mrna covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the Bnt162b2 covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven covid-19 vaccines as a third dose (Booster) following two doses of Chadox1 ncov-19 or Bnt162b2 in the uk (Cov-boost): A blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous Chadox1 ncov-19 and Bnt162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent sars-Cov-2 variants","volume":"75","author":"Gro\u00df","year":"2022","journal-title":"EBioMedicine"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the Bnt162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and efficacy of the mrna Bnt162b2 vaccine against sars-Cov-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00771-3","article-title":"Evaluation of antibody response to Bnt162b2 mrna covid-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination","volume":"22","author":"Firinu","year":"2022","journal-title":"Clin Exp Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221097","article-title":"Bnt162b2 vaccine-induced humoral and cellular responses against sars-Cov-2 variants in systemic lupus erythematosus","volume":"81","author":"Moyon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221508","article-title":"Immunogenicity of Bnt162b2 vaccine against the alpha and delta variants in immunocompromised patients with systemic inflammatory diseases","volume":"81","author":"Hadjadj","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the Bnt162b2 mrna covid-19 vaccine in people living with hiv-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B129","doi-asserted-by":"publisher","first-page":"103336","DOI":"10.1016\/j.drudis.2022.08.004","article-title":"The current status of covid-19 vaccines. a scoping review","volume":"27","author":"Rueda-Fern\u00e1ndez","year":"2022","journal-title":"Drug Discovery Today"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01446","article-title":"The covid-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.drudis.2021.10.016","article-title":"Calming the cytokine storm of covid-19 through inhibition of Jak2\/Stat3 signaling","volume":"27","author":"Gajjela","year":"2022","journal-title":"Drug Discovery Today"},{"key":"B132","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in covid-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.737406","article-title":"Il-7 in sars-Cov-2 infection and as a potential vaccine adjuvant","volume":"12","author":"Bekele","year":"2021","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/nri2711","article-title":"The regulation of il-10 production by immune cells","volume":"10","author":"Saraiva","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.003","article-title":"Covid-19: A new virus, but a familiar receptor and cytokine release syndrome","volume":"52","author":"Hirano","year":"2020","journal-title":"Immunity"},{"key":"B136","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"Jak-stat pathway inhibition and their implications in covid-19 therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.3390\/ijms23094545","article-title":"Immune signature of covid-19: In-depth reasons and consequences of the cytokine storm","volume":"23","author":"Nied\u017awiedzka-Rystwej","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/568543","article-title":"Pivotal roles of gm-csf in autoimmunity and inflammation","volume":"2015","author":"Shiomi","year":"2015","journal-title":"Mediators Inflammation"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1213395\/v1","article-title":"Gm-csf promotes immune response and survival in a mouse model of covid-19","author":"Potter","year":"2022","journal-title":"Res Sq"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe covid-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2020.05.009","article-title":"Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in covid-19","volume":"51","author":"Saha","year":"2020","journal-title":"Arch Med Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_615_20","article-title":"Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by covid-19, which is resistant to anakinra, tocilizumab, and janus kinase inhibitors","volume":"53","author":"Cure","year":"2021","journal-title":"Indian J Pharmacol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06158","article-title":"Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of covid-19","volume":"7","author":"Patel","year":"2021","journal-title":"Heliyon"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.ccc060","article-title":"Cytokine storm release syndrome and the prospects for immunotherapy with covid-19, part 4: The role of jak inhibition","author":"Calabrese","year":"2021","journal-title":"Cleve Clin J Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.1c00874","article-title":"Nanocurcumin potently inhibits sars-Cov-2 spike protein-induced cytokine storm by deactivation of Mapk\/Nf-Kb signaling in epithelial cells","volume":"5","author":"Sharma","year":"2022","journal-title":"ACS Appl Bio Mater"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153729","article-title":"Dehydrozingerone ameliorates lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress Via modulating the Mapk\/Nf-Kb pathway","volume":"92","author":"Tirunavalli","year":"2021","journal-title":"Phytomedicine"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/cells11091391","article-title":"Cannabinoids alleviate the lps-induced cytokine storm via attenuating Nlrp3 inflammasome signaling and Tyk2-mediated Stat3 signaling pathways in vitro","volume":"11","author":"Suryavanshi","year":"2022","journal-title":"Cells"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06827-7","article-title":"Arglabin could target inflammasome-induced Ards and cytokine storm associated with covid-19","volume":"48","author":"Manayi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.5414\/cp203890","article-title":"Covid-19: Cytokine storm Modulation\/Blockade with oral polyvalent immunoglobulins (Pvig, Kmp01d): A potential and safe therapeutic agent (Primum nil nocere)","volume":"58","author":"Sly","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.3390\/nano10112301","article-title":"Biomimetic nanoparticles potentiate the anti-inflammatory properties of dexamethasone and reduce the cytokine storm syndrome: An additional weapon against covid-19","volume":"10","author":"Molinaro","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154153","article-title":"Glycyrrhetinic acid: A potential drug for the treatment of covid-19 cytokine storm","volume":"102","author":"Li","year":"2022","journal-title":"Phytomedicine"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.765553","article-title":"Honeysuckle (Lonicera japonica) and huangqi (Astragalus membranaceus) suppress sars-Cov-2 entry and covid-19 related cytokine storm in vitro","volume":"12","author":"Yeh","year":"2021","journal-title":"Front Pharmacol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.853496","article-title":"Inspiration for covid-19 treatment: Network analysis and experimental validation of baicalin for cytokine storm","volume":"13","author":"You","year":"2022","journal-title":"Front Pharmacol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute covid-19 syndrome","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03553-9","article-title":"High-dimensional characterization of post-acute sequelae of covid-19","volume":"594","author":"Al-Aly","year":"2021","journal-title":"Nature"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac136","article-title":"Global prevalence of post covid-19 condition or long covid: A meta-analysis and systematic review","author":"Chen","year":"2022","journal-title":"J Infect Dis"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long covid in an international cohort: 7 months of symptoms and their impact","volume":"38","author":"Davis","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1111\/1468-0009.12505","article-title":"Long covid and health inequities: The role of primary care","volume":"99","author":"Berger","year":"2021","journal-title":"Milbank Q"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113426","article-title":"How and why patients made long covid","volume":"268","author":"Callard","year":"2021","journal-title":"Soc Sci Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00703-9","article-title":"A clinical case definition of post-Covid-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215818","article-title":"'Long-covid': A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for covid-19","volume":"76","author":"Mandal","year":"2021","journal-title":"Thorax"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048391","article-title":"Multiorgan impairment in low-risk individuals with post-Covid-19 syndrome: A prospective, community-based study","volume":"11","author":"Dennis","year":"2021","journal-title":"BMJ Open"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0896","article-title":"Autonomic dysfunction in 'Long covid': Rationale, physiology and management strategies","volume":"21","author":"Dani","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"B164","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/cells10020386","article-title":"Characterization and biomarker analyses of post-Covid-19 complications and neurological manifestations","volume":"10","author":"Sun","year":"2021","journal-title":"Cells"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(21)00084-5","article-title":"6-month neurological and psychiatric outcomes in 236\u2009379 survivors of covid-19: A retrospective cohort study using electronic health records","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309728","article-title":"The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia","volume":"65","author":"Schuijt","year":"2016","journal-title":"Gut"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2289","article-title":"Long-term side effects and lingering symptoms post covid-19 recovery","volume":"32","author":"Zarei","year":"2022","journal-title":"Rev Med Virol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/life12071066","article-title":"Covid-19 vaccine and long covid: A scoping review","volume":"12","author":"Mumtaz","year":"2022","journal-title":"Life (Basel)"},{"key":"B169","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1101\/2022.01.05.22268800","article-title":"Association between Bnt162b2 Vaccination and Reported Incidence of Post-Covid-19 Symptoms: Cross-Sectional Study 2020-21, Israel","volume":"7","author":"Kuodi","year":"2022","journal-title":"npj Vaccines"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069676","article-title":"Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study","volume":"377","author":"Ayoubkhani","year":"2022","journal-title":"Bmj"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac228","article-title":"The protective effect of coronavirus disease 2019 (Covid-19) vaccination on postacute sequelae of covid-19: A multicenter study from a Large national health research network","volume":"9","author":"Zisis","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with covid-19: An open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106688","article-title":"Subcutaneous administration of interferon beta-1a for covid-19: A non-controlled prospective trial","volume":"85","author":"Dastan","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (Il-6) blockade for coronavirus disease 2019 (Covid-19)-Induced cytokine release syndrome (Crs)","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/medicina58081076","article-title":"Assessment of tocilizumab (Humanized monoclonal antibody) for therapeutic efficacy and clinical safety in patients with coronavirus disease (Covid-19)","volume":"58","author":"Ullah","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.14336\/ad.2022.0205","article-title":"Effect of sars Cov2-neutralizing monoclonal antibody on hospitalization and mortality in long-term care facility residents","volume":"13","author":"Murillo","year":"2022","journal-title":"Aging Dis"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980435","article-title":"Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against sars-Cov-2","volume":"13","author":"Ji","year":"2022","journal-title":"Front Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104761","article-title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (Sars-Cov-2)","volume":"156","author":"Runfeng","year":"2020","journal-title":"Pharmacol Res"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.medntd.2022.100139","article-title":"Traditional Chinese medicine is effective for covid-19: A systematic review and meta-analysis","volume":"16","author":"Xu","year":"2022","journal-title":"Med Nov Technol Devices"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2022.115661","article-title":"Shufeng jiedu capsule inhibits inflammation and apoptosis by activating A2aar and inhibiting nf-Kb to alleviate lps-induced Ali","volume":"298","author":"Cai","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114303","article-title":"Active components in ephedra sinica stapf disrupt the interaction between Ace2 and sars-Cov-2 rbd: Potent covid-19 therapeutic agents","volume":"278","author":"Mei","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/14756366.2021.1873977","article-title":"Scutellaria baicalensis extract and baicalein inhibit replication of sars-Cov-2 and its 3c-like protease in vitro","volume":"36","author":"Liu","year":"2021","journal-title":"J Enzyme Inhib Med Chem"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113434","article-title":"Study on the potential of sanghuangporus sanghuang and its components as covid-19 spike protein receptor binding domain inhibitors","volume":"153","author":"Chien","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.926507","article-title":"Bioactive natural products in covid-19 therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"Mrna-lipid nanoparticle covid-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1002\/nano.202000125","article-title":"Nanoparticles-assisted delivery of antiviral-sirna as inhalable treatment for human respiratory viruses: A candidate approach against sars-Cov-2","volume":"1","author":"Ullah","year":"2020","journal-title":"Nano Sel"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2021.110753","article-title":"Nanomedicine formulations for respiratory infections by inhalation delivery: Covid-19 and beyond","volume":"159","author":"Zachar","year":"2022","journal-title":"Med Hypotheses"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1007\/s10570-021-04391-8","article-title":"Enhanced curcumin loaded nanocellulose: A possible inhalable nanotherapeutic to treat covid-19","volume":"29","author":"Gunathilake","year":"2022","journal-title":"Cellulose (Lond)"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.3390\/ph14101059","article-title":"Physicochemical characteristics and in vitro Toxicity\/Anti-Sars-Cov-2 activity of favipiravir solid lipid nanoparticles (Slns)","volume":"14","author":"Tulbah","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.592238","article-title":"Nasal delivery of Hesperidin\/Chitosan nanoparticles suppresses cytokine storm syndrome in a mouse model of acute lung injury","volume":"11","author":"Jin","year":"2020","journal-title":"Front Pharmacol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1080\/1061186x.2021.1971236","article-title":"Characteristics of sars-Cov2 that may be useful for nanoparticle pulmonary drug delivery","volume":"30","author":"Rabiei","year":"2022","journal-title":"J Drug Target"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113499","article-title":"A comprehensive insight into current control of covid-19: Immunogenicity, vaccination, and treatment","volume":"153","author":"Mohamed","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2007015","article-title":"Heterologous prime-boost vaccination against covid-19: Is it safe and reliable","volume":"17","author":"Choudhary","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-022-01146-1","article-title":"Role of drug delivery technologies in the success of covid-19 vaccines: A perspective","volume":"12","author":"Labouta","year":"2022","journal-title":"Drug Delivery Transl Res"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.631226","article-title":"Inflammation and antiviral immune response associated with severe progression of covid-19","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119437","article-title":"Nanocurcumin improves treg cell responses in patients with mild and severe sars-Cov2","volume":"276","author":"Tahmasebi","year":"2021","journal-title":"Life Sci"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.06.017","article-title":"Cytokines and micrornas in sars-Cov-2: What do we know","volume":"29","author":"Rarani","year":"2022","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1035151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:29:37Z","timestamp":1667496577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1035151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":197,"alternative-id":["10.3389\/fimmu.2022.1035151"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1035151","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"article-number":"1035151"}}